Mild symptoms: cessation of the neuroleptic drug or decreasing the dose, which rarely reverses symptoms
Moderate to severe symptoms: reserpine and tetrabenazine
New drug approved 2017
Austedo (deutetrabenazine), previously approved for chorea due to Huntington's disease
12-48 mg/day PO divided BID, starting at 6 mg BID, increased by 6 mg/day qwk
Austedo (deutetrabenazine), previously approved for chorea due to Huntington's disease
12-48 mg/day PO divided BID, starting at 6 mg BID, increased by 6 mg/day qwk
Tardive dyskinesia
See DDX for chorea
Akathisia
Chorea
Botulism
Sydenham's chorea
Opsoclonus
Tick paralysis